Long-term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy Journal Article

   

Authors:	Cowzer, D.; Soares, K.; Walch, H.; Gönen, M.; Boucher, T. M.; Do, R. K. G.; Harding, J. J.; Varghese, A. M.; Reidy-Lagunes, D.; Saltz, L.; Connell, L. C.; Abou-Alfa, G. K.; Wei, A. C.; Schultz, N.; Kingham, T. P.; D'Angelica, M.; Drebin, J. A.; Balachandran, V.; Sanchez-Vega, F.; Kemeny, N. E.; Jarnagin, W. R.; Cercek, A.
Article Title:	Long-term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy
Abstract:	Background Hepatic artery infusion of chemotherapy has demonstrated disease control and suggested improvement in overall survival in intrahepatic cholangiocarcinoma. We report herein the long-term results and role of molecular alterations of a phase II clinical trial of hepatic artery infusion chemotherapy plus systemic chemotherapy, with a retrospective cohort of patients treated with hepatic artery infusion at Memorial Sloan Kettering Cancer Center.Methods This is a secondary analysis of a single-institution, phase II trial, and retrospective cohort of unresectable intrahepatic cholangiocarcinoma treated with hepatic artery infusion floxuridine plus systemic gemcitabine and oxaliplatin. The primary aim was to assess long-term oncologic outcomes. A subset underwent tissue-based genomic sequencing, and molecular alterations were correlated with progression-free survival (PFS) and overall survival.Results A total of 38 patients were treated on trial with a median follow-up of 76.9 months. Median PFS was 11.8 months (95% confidence interval [CI] = 11 to 15.1 months). The median overall survival was 26.8 months (95% CI = 20.9 to 40.6 months). The 1-, 2-, and 5-year overall survival rate was 89.5%, 55%, and 21%, respectively. Nine (24%) patients received hepatic artery infusion with mitomycin C post-floxuridine progression with an objective response rate of 44% and a median PFS of 3.93 months (95% CI = 2.33 months to not reached). A total of 170 patients not treated on the clinical trial were included in a retrospective analysis. Median PFS and overall survival were 7.93 months (95% CI = 7.27 to 10.07 months) and 22.5 months (95% CI = 19.5 to 28.3 months), respectively. Alterations in the TP53 and cell-cycle pathway had a worse PFS to hepatic artery infusion-based therapy compared with wild-type disease.Conclusion In locally advanced intrahepatic cholangiocarcinoma, hepatic artery infusion with floxuridine in combination with systemic therapy can offer long-term durable disease control. Molecular alterations may predict for response.
Keywords:	multicenter; primary liver-cancer
Journal Title:	JNCI: Journal of the National Cancer Institute
Volume:	117
Issue:	2
ISSN:	0027-8874
Publisher:	Oxford University Press
Date Published:	2025-02-01
Start Page:	279
End Page:	286
Language:	English
ACCESSION:	WOS:001322843700001
DOI:	10.1093/jnci/djae202
PROVIDER:	wos
PMCID:	PMC11807433
PUBMED:	39331613
Notes:	The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PubMed record and PDF. Corresponding MSK author is Andrea Cercek -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/223058